(Reuters) – Catalent Inc posted a bigger-than-expected loss on Monday, hurt by persistent production-related challenges at the contract drug manufacturer’s major facilities
Excluding items, the company’s third-quarter loss was 9 cents per share, compared with analysts’ average estimates for a loss of 3 cents, according to Refinitiv data.
(Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri and Devika Syamnath)
